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on around 40-50% of imported products while the medical electronics ($1.57 billion), 
hospital equipments ($0.39 billion), implants ($0.20 billion) and diagnostics ($0.09 
billion) categories on around 85-90%. Due to more dependency on imported products 
as well as absence of regulations for prices in India, doctors, hospitals and retailers 
overcharged the patients almost three to four times for certain devices e.g. Drug 
eluting stents (DES) manufactured by Abbott imported at $640 and sold at $2000, 
a mark-up of over 250% and that manufactured by Medtronics imported at $485 
and sold at $2600, a mark-up of more than 400%. Recognising this policy deficit, 
the Department of Pharmaceuticals under the Ministry of Chemicals & Fertilizers, 
has published draft proposals which is National Medical Device Policy-2015 for 
the medical devices approval & pricing regulations. These proposals have recom-
mended creating an autonomous body, the National Medical Devices Authority 
(NDMA) for pricing control of medical devices by including them under the Essential 
Commodities Act or through a Medical Devices Prices Control Order(MDPCO) 
and creating a separate pricing division in the National Pharmaceuticals Pricing 
Authority(NPPA). Ispor-India chapter has developed Pharmacoeconomic guidelines 
which will also include the above mentioned devices and the same will be presented 
in this presentation along with our survey data.
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Recently, the need for health services has increased gradually and the limita-
tions in sources allocated for this area have been recognized.According to Danzon 
(2001), arrangements towards controlling the expenses through price,profit con-
trols and reimbursement methods This study examines;current situation in 
Turkey and Ukraine, pharmaceutical pricing methods, reimbursement methods 
and basic health indicators within the scope of changing pharmaceutical poli-
cies in Turkey and Ukraine. It was detected that the pharmaceutical pricing in 
Turkey has been performed on the basis of the reference pricing system that takes 
Italy,Portugal,Spain,Greece and France as reference. The regulations regarding the 
reimbursement process are determined by SSI. In Ukraine there are margin control 
and reference pricing methods only for the medicines that may be public purchased 
and are included in the National list of medicines and the list of medicines “On the 
procedure of procurement of medicines by health institutions financed from the 
public budget”. Reimbursement method was applied only for one pilot project on 
antihypertensive medicines in 2012 because state health insurance system has 
not yet implemented. Due to the resolution of Cabinet of ministers of Ukraine “On 
reference pricing for medicines and medical products, purchased by the state and 
local budgets reference pricing is implemented for medicines, which are included in 
the list of medicines that have margin control and may be purchased within public 
budgets. Reference pricing is based on the international comparison with prices in 
mainly eastern Europe countries. Coverage of government was 13% of the Ukrainian 
pharmaceutical market The reimbursement system of Turkey has been changed 
numerous times and the discount rates has incrementally risen. Ukraine has just 
began implementing pricing and reimbursement for medicines. It is understand that 
Turkey has been done policies already but Ukraine has just began implementations. 
Our study shows impact of Turkish reforms and expected from Ukraine.
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Objectives: Health Professionals in Africa in an attempt to improve healthcare 
delivery have brought up well thought out ways to offer better health care service, 
but for their lack of involvement in Politics and Legislation in their countries, efforts 
to implement their proposals have been met with brick walls. The Objective of this 
conceptual paper is to emphasis the need for Healthcare providers to be involved in 
Policy making in their countries, to champion health care policies that will improve 
health care delivery. MethOds: Using Nigeria as case study. I sort the views of 
several health professionals through their articles on Improving Healthcare delivery 
in Nigeria published in popular Journals and magazines. I consulted magazines and 
Journals from more advanced countries to seek out ways through which they have 
improved their health care system. Results: Of all the views presented by these 
health professionals (Pharmacist and Medical Doctors), most pointed towards the 
role of the government in improving the healthcare sector, others suggested a need 
for health professionals to be involved in Politics without emphasizing on it. While 
in my analysis of the systems in the developed countries, I discovered that health-
care providers were involved in the government not as executive but as legislatures, 
this way they sponsor health related bills and policies and were able to improve the 
value of healthcare delivery. cOnclusiOns: To improve healthcare delivery and 
patient care in Africa, Health care givers (pharmacist and doctors) should be part 
of the countries policy makers (legislatures) so as to drive the needed transforma-
tion in the health sector.
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Nepal is a topographically vulnerable country for many life threatening disasters 
like earthquake, landslides, avalanche, floods etc. Health care policy should focus on 
the disaster management plan and quick relief programs following major disasters. 
According to National consensus, 8151 people have been killed and 17,886 left injured. 
Nepal’s earthquake economic toll is massive in the health sector too. Many hospitals 
on media to dispute sofosbuvir price considered as scandalous, while compliant 
with French regulation. French Health Minister organized a European coalition to 
control its price. Under tremendous media, political and administrative pressure, 
the manufacturer accepted significant price decrease, early entry agreement in 
France and later in most EU countries. Following this saga, to ensure drug budget 
will remain under control, most EU countries issued regulation or law to cap drug 
budget expenditure for HCV. cOnclusiOn: This case highlights limit of current 
pricing policies which are unable to match affordability and drug prices. Even 
if cost effectiveness remains important information for efficiency assessment, 
sofosbuvir case confirms the inability of cost-effectiveness analysis to address 
affordability issue. Budget impact in supporting decision making will become 
more and more critical in the future.
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bAckgROund: Cancer imposes enormous financial burden to society. Direct medi-
cal costs were estimated at around € 51 billion across European (EU) countries (2009) 
and $88.7 billion in the United-States (US) (2011). The concept of “financial toxicity” 
has been first reported by US academic oncologists, Zafar and Abernathy in 2013. 
It refers to financial distress linked to out-of-pocket payments of costly oncology 
drugs (OD). This critical concept led to the development of a patient-reported out-
come questionnaire by de Souza et al. This conceptual research aimed to address 
aspects of oncology drug financial toxicity (ODFT) and how the US and European 
Union countries cope with high OD prices. discussiOn: ODFT has been reported 
to affect patient’s quality of life and treatment adherence. In US, ODFT is related to 
the positioning in specialty care tier (fourth or fifth tier), leaving a high co-pay for 
the patients. Moreover, 13% of the US population is uninsured (2013). This issue is 
not new; in 2007, a study reported that 16% of oncologist did not propose expensive 
products to some patients based on their perception of patient affordability. In EU, 
the coverage system is quite different and operates as an on/off system, protect-
ing patients from ODFT. Patients are either 100% covered for all reimbursed drugs 
(France, UK, Germany, Spain, Italy), or drugs are not recommended/reimbursed and 
then not proposed to the patients nor requested by the patients. The level of avail-
ability of these treatments might substantially differ between countries; high access 
of cancer drugs seen in France and Germany, while more restricted access seen 
in Spain, Italy and the UK. cOnclusiOns: EU inhabitants will remain protected 
from ODFT as long as reimbursement process remains an on/off system (100% or 
0% coverage) and off-reimbursement use is exceptional. ODFT will remain specific 
to the US and possibly to emerging countries.
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bAckgROund: The South African Pharmacoeconomic Guidelines were published 
in February 2013, with the intention for application to newly approved medicines in 
the privates sector. However, uptake has been poor and the number of submissions 
negligible. Objectives: This study aims to examine the pharmacoeconomic guide-
lines in the context of existing legislation, policy and incentives in the private sector 
in South Africa to make explicit the reasons for the poor uptake and challenges to 
implementing the guidelines. MethOds: A review of existing legislation regulating 
reimbursement of medicines in the private sector was undertaken in relation to 
the implementation of the guidelines, as well as interviews with key stakeholders 
in the pharmaceutical industry, ministry of health and health insurance industries 
to understand attitudes to and challenges to adopting the guidelines submission 
criteria and results. Results: Existing legislation means that results of pharmaco-
economic submissions are not enforceable – funders are not required reimburse for 
products should the ministry of health evaluations process deem them cost-effec-
tive. Pharmaceutical companies are thus at risk of a negative finding on reimburse-
ment with no assurance that a positive finding will improve reimbursement for new 
products. As submission is currently not mandatory, this is something they will be 
unlikely to do. The level of strict application or flexibility within the requirements 
of the guidelines is also not clear. cOnclusiOns: Uptake and engagement with the 
South African Pharmacoeconomic Guidelines has been poor, with no submissions 
formally evaluated since the guidelines were finalised. Several existing policy and 
legislative barriers exist which make the success of these guidelines in this current 
environment unlikely. Building capacity for submitting analyses as well as within 
the ministry of health to evaluate submissions will be critical.
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In India, medical device industry is a multi-product industry covering the entire 
gamut from disposable gloves and syringes to high-end machines like CT scans 
and robotic surgery machines and worth $5 billion approximately growing at a 
Compound Annual Growth Rate (CAGR) of 15%. Over 75% of medical devices market 
is dependent on imports, mostly by multinationals that have no manufacturing facil-
ity in India. According to a survey conducted by us, the disposables ($1.57 billion), 
consumables ($0.83 billion) and surgical instruments ($0.06 billion) market depends 
